How Ozempic is Changing Dating: GLP-1 Weight Loss Medications Are Reshaping Body Confidence, Desire, and Stigma

BackgroundRecent increases in the use of glucagon-like peptide-1 receptor agonists (GLP-1s) have generated widespread public interest in their physical and psychological effects, yet little research has examined how these medications may shape romantic and sexual experiences.AimThe present study investigated associations between GLP-1 use for weight loss and dating outcomes, sexual experiences, and perceived stigma among single adults in the United States.MethodsParticipants were 2,002 demographically representative single adults residing in the United States who completed measures assessing GLP-1 use, perceived changes in dating and sexual experiences, and concerns about judgment related to medication use.OutcomesPrimary outcomes included perceived changes in dating experiences, sexual experiences, confidence, sexual functioning, and stigma associated with GLP-1 use.ResultsOverall, 7.7% of participants reported using GLP-1 medications for weight loss in the past year. Among users, approximately one-third reported improvements in their dating lives and sex lives, although substantial variability emerged across outcomes. Some participants reported increased confidence, greater dating engagement, improved sexual functioning, and enhanced body comfort, whereas others reported reduced dating interest, lower confidence, or worsened sexual experiences. Gender differences also emerged. Men were more likely than women to report increases in dating confidence, changes in dating behavior, improvements in sexual functioning, and greater concern about being judged for using GLP-1 medications. Women were more likely to report no changes in sexual outcomes and lower concern about stigma.Clinical TranslationHealthcare and mental health professionals should recognize that GLP-1 medications may meaningfully shape patients’ romantic confidence, sexual experiences, and stigma concerns, highlighting the importance of addressing psychosocial and relational changes, not just physical outcomes, when initiating and managing GLP-1 treatment.Strengths and LimitationsStrengths of the study include the use of a large, demographically representative sample and the examination of an emerging but understudied topic related to sexuality and relationships. Limitations include cross-sectional design, reliance on self-reported outcomes, and inability to determine causal associations between GLP-1 use and relational or sexual experiences.ConclusionThe findings suggest that the relational and sexual consequences of GLP-1 use are heterogeneous and embedded within broader gendered, relational, and sociocultural contexts.